NCT02598661 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 57
- group Id
- BG001
- value
- 118
- group Id
- BG002
- value
- 60
- group Id
- BG003
- value
- 35
- group Id
- BG004
- value
- 18
- group Id
- BG005
- value
- 288
- units
- Participants
- groups
- description
- Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first. Dose escalation to 9.4 mg/kg was allowed before Protocol Amendment 2.
- id
- BG000
- title
- Phase 2: Imetelstat Sodium
- description
- Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.
- id
- BG001
- title
- Phase 3: Imetelstat Sodium
- description
- Imetelstat sodium-matching placebo administered IV, every 4 weeks (on a 28-day cycle), until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.
- id
- BG002
- title
- Phase 3: Placebo
- description
- Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.
- id
- BG003
- title
- QTc Substudy: Imetelstat Sodium
- description
- Imetelstat sodium-matching placebo administered IV, every 4 weeks (on a 28-day cycle), until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first. If after a minimum of 2 treatment cycles a participant has no significant change to pRBC transfusion burden or evidence of clinical benefit per Investigator, after discussion with the Sponsor the participant, he/she may be permitted to start treatment with imetelstat sodium.
- id
- BG004
- title
- QTc Substudy: Placebo
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 46
- upper Limit
- 83
- value
- 70.1
- group Id
- BG001
- lower Limit
- 44
- upper Limit
- 87
- value
- 70.4
- group Id
- BG002
- lower Limit
- 39
- upper Limit
- 85
- value
- 71.7
- group Id
- BG003
- lower Limit
- 43
- upper Limit
- 84
- value
- 69.7
- group Id
- BG004
- lower Limit
- 54
- upper Limit
- 81
- value
- 67.8
- group Id
- BG005
- lower Limit
- 39
- upper Limit
- 87
- value
- 69.9
- dispersion Type
- FULL_RANGE
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 47
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 102
- title
- Female
- measurements
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 71
- group Id
- BG002
- value
- 40
- group Id
- BG003
- value
- 27
- group Id
- BG004
- value
- 16
- group Id
- BG005
- value
- 186
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 12
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 48
- group Id
- BG001
- value
- 100
- group Id
- BG002
- value
- 48
- group Id
- BG003
- value
- 29
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 240
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 36
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 15
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 6
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 48
- group Id
- BG003
- value
- 29
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 233
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 34
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Phase 2: All Treated Analysis Set included all participants who received at least one dose of study drug. Phase 3: Intent-to-Treat (ITT) Analysis Set included all participants randomized into the phase 3 study. The QTc Substudy Analysis Set included all participants who participated in QTc Substudy and received at least one dose of study drug.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 57
- group Id
- BG001
- value
- 118
- group Id
- BG002
- value
- 60
- group Id
- BG003
- value
- 35
- group Id
- BG004
- value
- 18
- group Id
- BG005
- value
- 288
- units
- Participants
- groups
- description
- Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first. Dose escalation to 9.4 mg/kg was allowed before Protocol Amendment 2.
- id
- BG000
- title
- Phase 2: Imetelstat Sodium
- description
- Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.
- id
- BG001
- title
- Phase 3: Imetelstat Sodium
- description
- Imetelstat sodium-matching placebo administered IV, every 4 weeks (on a 28-day cycle), until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.
- id
- BG002
- title
- Phase 3: Placebo
- description
- Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.
- id
- BG003
- title
- QTc Substudy: Imetelstat Sodium
- description
- Imetelstat sodium-matching placebo administered IV, every 4 weeks (on a 28-day cycle), until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first. If after a minimum of 2 treatment cycles a participant has no significant change to pRBC transfusion burden or evidence of clinical benefit per Investigator, after discussion with the Sponsor the participant, he/she may be permitted to start treatment with imetelstat sodium.
- id
- BG004
- title
- QTc Substudy: Placebo
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 46
- upper Limit
- 83
- value
- 70.1
- group Id
- BG001
- lower Limit
- 44
- upper Limit
- 87
- value
- 70.4
- group Id
- BG002
- lower Limit
- 39
- upper Limit
- 85
- value
- 71.7
- group Id
- BG003
- lower Limit
- 43
- upper Limit
- 84
- value
- 69.7
- group Id
- BG004
- lower Limit
- 54
- upper Limit
- 81
- value
- 67.8
- group Id
- BG005
- lower Limit
- 39
- upper Limit
- 87
- value
- 69.9
- dispersion Type
- FULL_RANGE
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 47
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 102
- title
- Female
- measurements
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 71
- group Id
- BG002
- value
- 40
- group Id
- BG003
- value
- 27
- group Id
- BG004
- value
- 16
- group Id
- BG005
- value
- 186
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 12
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 48
- group Id
- BG001
- value
- 100
- group Id
- BG002
- value
- 48
- group Id
- BG003
- value
- 29
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 240
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 36
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 15
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 6
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 48
- group Id
- BG003
- value
- 29
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 233
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 34
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Phase 2: All Treated Analysis Set included all participants who received at least one dose of study drug. Phase 3: Intent-to-Treat (ITT) Analysis Set included all participants randomized into the phase 3 study. The QTc Substudy Analysis Set included all participants who participated in QTc Substudy and received at least one dose of study drug.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle